A dose-escalation study of SAR3419, an anti-CD19 antibody maytansinoid conjugate, administered by intravenous infusion once weekly in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.

@article{Ribrag2014ADS,
  title={A dose-escalation study of SAR3419, an anti-CD19 antibody maytansinoid conjugate, administered by intravenous infusion once weekly in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.},
  author={Vincent Ribrag and Jehan Dupuis and Herv{\'e} Tilly and Franck Morschhauser and Fabrice Laine and Roch Houot and Corinne Haioun and Christiane Copie and Andrea Varga and John W. Lambert and Laurence Hatteville and Samira Ziti-Ljajic and Anne Caron and Sandrine Payrard and Bertrand Coiffier},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2014},
  volume={20 1},
  pages={213-20}
}
PURPOSE To determine recommended dose, dose-limiting toxicity, safety profile, pharmacokinetics, preliminary antitumor activity, and exploratory pharmacodynamics of SAR3419, an antibody-drug conjugate targeting CD19, administered alone by intravenous infusion weekly (qw), in a dose-escalation phase I study in patients with refractory/relapsed (R/R) non-Hodgkin lymphoma (NHL). EXPERIMENTAL DESIGN Patients with R/R CD19(+) B-NHL were treated with escalating doses of SAR3419 repeated qw for… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 32 extracted citations

Current status of antibody therapy in ALL.

British journal of haematology • 2015
View 7 Excerpts
Highly Influenced

Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma

Annals of oncology : official journal of the European Society for Medical Oncology • 2018
View 1 Excerpt

References

Publications referenced by this paper.
Showing 1-10 of 45 references

Antibody conjugate therapeutics: challenges and potential.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2011
View 7 Excerpts
Highly Influenced

Effect of anti-CD19 BiTE blinatumomab on complete remission rate and overall survival in adult patients with relapsed/refractory Bprecursor ALL

ToppM, N Goekbuget, +3 authors S Neumann
J Clin Oncol • 2012

Evaluation of combination therapies with MOR00208, an Fc-enhanced humanized CD19 antibody, in models of lymphoma

M Winderlich, D Ness, S Steidl, J. Endell
J Clin Oncol • 2012

Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2012

Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2011
View 1 Excerpt

Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2011
View 1 Excerpt

Similar Papers

Loading similar papers…